Home
About
Research
Blog
Development
Contact
Products
News
Recently, the company was concerned about the U.S. FDA's announcement on November 28, 2023, on individual reports of T-cell tumors in patients receiving targeted BCMA or CD19 autologous CAR-T cell immunotherapy. The FDA said, "While the overall benefits of the approved uses of these products continue to exceed their potential risks, the FDA is evaluating the need for regulatory action1."
Key words:Enterprise Newsrecentlycompanyconcerned
CAR-T major good! National Institute for Health and Clinical Excellence (NICE) approves NHS regular use of CAR-T for diffuse large B- cell lymphoma
Key words:Enterprise Newscar-tmajornational
In recent years, with the continuous progress of cell therapy technology, the word CAR-T has begun to appear frequently in the public eye, and the news of the 1.2 million of an anti-cancer drug is still fresh in the memory of many friends. For ordinary cancer patients and families, the launch of CAR-T products is both gratifying and worrying. On the one hand, it is the hope of survival, and on the other hand, it is the "sky-high price" that countless people cannot afford 』.
Key words:Enterprise Newsyearscontinuousprogress
[Information] | Hubei Daily: Major Breakthrough in Treatment of Solid Tumors by CAR-T Cell Technology in Han
Key words:Enterprise Newsinformationdailymajor